Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24: The VALOR-HCM Trial
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3… View more

Heart Failure
Early Ventricular Septal Rupture following Acute Myocardial Infarction Diagnosed on Left Ventriculogram
Author(s): Arpanjeet Kaur , Yash Patel , Jacqueline Tamis-Holland Added: 1 year ago

Imaging & Diagnostics

MI/ACS
Novel Therapies in ATTR-CM
Author(s): Michelle Dimza , Georgia Vasilakis , Justin L Grodin Added: 4 months ago

Heart Failure
Device Therapies in Heart Failure
Author(s): Yoel Benarroch , Natalie Tapaskar , Amin Yehya Added: 5 months ago

Heart Failure

Intervention
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 3 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 3 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Definitions and Implications of Shock Diagnosis and Therapy with Dr Frederick Welt
Author(s): Frederick Welt Added: 5 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick… View more

Heart Failure

Intervention
ESC 25: Lifetime Benefits of Combination Therapy in HFpEF
Author(s): Muthiah Vaduganathan Added: 6 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient… View more

Heart Failure
NOAC Monotherapy Noninferior to Combo Therapy Post-DES
Added: 1 week ago Source:  Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,… View more

Anticoagulation

Electrophysiology & Arrhythmia
Inverted Tulip Deformation
Author(s): Kevin Velarde-Acosta , Josh Yefry Moscoso Ramirez , Paol Jhullian Rojas , et al Added: 7 months ago

Imaging & Diagnostics

Intervention